EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity

Lindsay B Alcaraz iD, Aude Mallavialle iD, Caroline Mollevi iD, Florence Boissière-Michot, Hanane Mansouri, Joelle Simony-Lafontaine, Valérie Laurent-Matha iD, Thierry Chardès iD, William Jacot iD, Andrei Turtoi iD, Pascal Roger iD, Séverine Guiu iD und 1 weitere

International Journal of Cancer · 15.03.2023 · 152 (6) · 1243-1258

DOI: 10.1002/ijc.34345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 30.11.2022. Verfasst von Lindsay B Alcaraz und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cancer-Associated Fibroblasts, Antineoplastic Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype and lacks specific targeted therapeutic agents. The current mechanistic evidence from cell‐based studies suggests that the matricellular protein SPARC has a tumor‐promoting role in TNBC; however, data on the clinical relevance of SPARC expression/secretion by tumor and stromal cells in TNBC are limited. Here, we analyzed by immunohistochemistry the prognostic value of tumor and stromal cell SPARC expression in 148 patients with non‐metastatic TNBC and long follow‐up (median: 5.4 years). We also quantified PD‐L1 and PD‐1 expression. We detected SPARC expression in tumor cells (42.4%), cancer‐associated fibroblasts (CAFs; 88.1%), tumor‐associated macrophages (77.1%), endothelial cells (75.2%) and tumor‐infiltrating lymphocytes (9.8%). Recurrence‐free survival was significantly lower in patients with SPARC‐expressing CAFs. Multivariate analysis showed that SPARC expression in CAFs was an independent prognostic factor. We also detected tumor and stromal cell SPARC expression in TNBC cytosols, and in patient‐derived xenografts and cell lines. Furthermore, we analyzed publicly available single‐cell mRNA sequencing data and found that in TNBC, SPARC is expressed by different CAF subpopulations, including myofibroblasts and inflammatory fibroblasts that are involved in tumor‐related processes. We then showed that fibroblast‐secreted SPARC had a tumor‐promoting role by inhibiting TNBC cell adhesion and stimulating their motility and invasiveness. Overall, our study demonstrates that SPARC expression in CAFs is an independent prognostic marker of poor outcome in TNBC. Patients with SPARC‐expressing CAFs could be eligible for anti‐SPARC targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCancer-Associated FibroblastsAntineoplastic AgentsHumansPrognosisEndothelial CellsBiomarkers, TumorOsteonectin

Stichwörter der Autor:innen

CAFSPARCTNBCosteonectinsingle-cell mRNA sequencing

Substanzen

Antineoplastic AgentsBiomarkers, TumorSPARC protein, humanOsteonectin

Autor:innen und Institutionen

  • IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
  • Biometry Unit, ICM, University of Montpellier, Montpellier, France.
  • Desbrest Institute of Epidemiology and Public Health, University of Montpellier, INSERM, Montpellier, France.
  • Translational Research Unit, ICM, Montpellier, France.
  • RHEM, IRCM, Montpellier, France.
  • Department of Medical Oncology, ICM, Montpellier, France.

ORCID-Profile: Lindsay B Alcaraz, Aude Mallavialle, Caroline Mollevi, Valérie Laurent-Matha, Thierry Chardès, William Jacot, Andrei Turtoi, Pascal Roger, Séverine Guiu, Emmanuelle Liaudet-Coopman

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Alcaraz, L. B., Mallavialle, A., Mollevi, C., Boissière-Michot, F., Mansouri, H., Simony-Lafontaine, J., Laurent-Matha, V., Chardès, T., Jacot, W., Turtoi, A., Roger, P., Guiu, S., & Liaudet-Coopman, E. (2023). SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity. International Journal of Cancer, 152(6), 1243-1258. https://doi.org/10.1002/ijc.34345

Vancouver

Alcaraz LB, Mallavialle A, Mollevi C, Boissière-Michot F, Mansouri H, Simony-Lafontaine J, et al. SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity. International Journal of Cancer. 2023;152(6):1243-1258. doi:10.1002/ijc.34345

BibTeX
@article{Alcaraz2023,
  author = {Alcaraz, Lindsay B and Mallavialle, Aude and Mollevi, Caroline and Boissière-Michot, Florence and Mansouri, Hanane and Simony-Lafontaine, Joelle and Laurent-Matha, Valérie and Chardès, Thierry and Jacot, William and Turtoi, Andrei and Roger, Pascal and Guiu, Séverine and Liaudet-Coopman, Emmanuelle},
  title = {SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {6},
  pages = {1243--1258},
  doi = {10.1002/ijc.34345}
}
Kostenlos starten →